Your browser doesn't support javascript.
loading
Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
Long, Lin; Xu, Jiachi; Qi, Xiaowen; Pen, Yan; Wang, Chengkun; Jiang, Weifan; Peng, Xue; Hu, Zecheng; Yi, Wenjun; Xie, Liming; Lei, Xiaoyong; Wang, Zhen; Zhuo, Linsheng.
Affiliation
  • Long L; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Xu J; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China; Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
  • Qi X; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Pen Y; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Wang C; Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Jiang W; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Peng X; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Hu Z; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Yi W; Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
  • Xie L; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China. Electronic address: xieliming2019@usc.edu.cn.
  • Lei X; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China. Electronic address: leix_yong@163.com.
  • Wang Z; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China; National Health Commission Key Laboratory of Birth Defect Research and Prevention
  • Zhuo L; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China; National Health Commission Key Laboratory of Birth Defect Research and Prevention
Eur J Med Chem ; 273: 116500, 2024 Jul 05.
Article in En | MEDLINE | ID: mdl-38776807
ABSTRACT
The deficiency in available targeted agents and frequency of chemoresistance are primary challenges in clinical management of triple-negative breast cancer (TNBC). The aberrant expression of USP21 and JAK2 represents a characterized mechanism of TNBC progression and resistance to paclitaxel (PTX). Despite its clear that high expression of USP21-mediated de-ubiquitination leads to increased levels of JAK2 protein, we lack regulator molecules to dissect the mechanisms that the interaction between USP21 and JAK2 contributes to the phenotype and resistance of TNBC. Here, we report a USP21/JAK2/STAT3 axis-targeting regulator 13c featuring a N-anthraniloyl tryptamine scaffold that showed excellent anti-TNBC potency and promising safety profile. Importantly, the therapeutic potential of using 13c in combination with PTX in PTX-resistant TNBC was demonstrated. This study showcases N-anthraniloyl tryptamine derivatives as a novel anti-TNBC chemotype with a pharmacological mode of action targeting the USP21/JAK2/STAT3 axis and provides a potential therapeutic target for the treatment of TNBC.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ubiquitin Thiolesterase / STAT3 Transcription Factor / Janus Kinase 2 / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Eur J Med Chem Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ubiquitin Thiolesterase / STAT3 Transcription Factor / Janus Kinase 2 / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Eur J Med Chem Year: 2024 Document type: Article